



**UNIVERSIDADE ESTADUAL DE MARINGÁ**  
**CENTRO DE CIÊNCIAS AGRÁRIAS**  
Programa de Pós-Graduação em Ciência de Alimentos

**EFEITOS DA PASTEURIZAÇÃO E LIOFILIZAÇÃO  
SOBRE A COMPOSIÇÃO PROXIMAL, COMPOSIÇÃO  
EM ÁCIDOS GRAXOS E QUALIDADE LIPÍDICA DO  
LEITE HUMANO COLOSTRO**

**GISLAINE DE ALMEIDA SANTANA IENTZ**

Maringá

2023

Dados Internacionais de Catalogação-na-Publicação (CIP)  
(Biblioteca Central - UEM, Maringá - PR, Brasil)

I22e

lentz, Gislaine Almeida Santana

Efeitos da pasteurização e liofilização sobre a composição proximal, composição em ácidos graxos e qualidade lipídica do leite humano colostro / Gislaine Almeida Santana lentz. -- Maringá, PR, 2023.

37 f.: il. color., figs., tabs.

Orientador: Prof. Dr. Jesuí Vergílio Visentainer.

Dissertação (Mestrado) - Universidade Estadual de Maringá, Centro de Ciências Agrárias, Programa de Pós-Graduação em Ciência de Alimentos, 2023.

1. Ácidos graxos. 2. Cromatografia gasosa. 3. Colostro. 4. Leite humano. 5. Macronutrientes. I. Visentainer, Jesuí Vergílio, orient. II. Universidade Estadual de Maringá. Centro de Ciências Agrárias. Programa de Pós-Graduação em Ciência de Alimentos. III. Título.

CDD 23.ed. 637.17

Rosana de Souza Costa de Oliveira - 9/1366

**GISLAINE DE ALMEIDA SANTANA IENTZ**

**“EFEITOS DA PASTEURIZAÇÃO E LIOFILIZAÇÃO SOBRE A COMPOSIÇÃO PROXIMAL, COMPOSIÇÃO EM ÁCIDOS GRAXOS E QUALIDADE LIPÍDICA DO LEITE HUMANO COLOSTRO”.**

Dissertação apresentada à Universidade Estadual de Maringá, como parte das exigências do Programa de Pós-graduação em Ciência de Alimentos, para obtenção do grau de Mestre em Ciência de Alimentos.



---

**Profa. Dra. Grasiela Scaramal Madrona**



---

**Profa. Dra. Patricia Daniele Silva dos Santos**



---

**Prof. Dr. Jesuí Vergílio Visentainer**  
**Orientador**

Maringá – 2023

**Orientador**

Jesuí Vergílio Visentainer

## **BIOGRAFIA**

Gislaine de Almeida Santana Ientz nasceu em 11 de outubro de 1988, em Curitiba, Paraná. Possui graduação em Engenharia de Alimentos pela Universidade Estadual do Paraná. Tem atuado em empresas privadas desde 2010, principalmente nas áreas de pesquisa e desenvolvimento de novos produtos, assuntos regulatórios e qualidade.

***Dedico***

Aos meus pais, Atacilio e Isaides, e ao meu esposo, Thiago.

## **AGRADECIMENTOS**

Ao Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), à Coordenação e Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação Araucária, Fundação Cargill e Programa de Pesquisa para o SUS (PPSUS).

Ao grupo de pesquisa APLE-A.

Ao Banco de Leite Humano da Universidade Estadual de Maringá.

Ao meu esposo, Thiago Ientz, que não me deixou esquecer do sonho antigo de fazer mestrado. Me incentivou e acreditou sempre.

Às amigas que me encorajaram com seus exemplos, Adriana Magagnin e Luíza Fietz.

E a Deus. Ele pode estar descrito no último parágrafo, mas Ele é o primeiro, vem antes de tudo. Ele não apenas coloca sonhos em meu coração, mas me direciona e ajuda para que eles possam ser concretizados. E dessa vez a ajuda veio em forma de pessoas maravilhosas colocadas em meu caminho: Prof. Dr. Jesuí Visentainer, que aceitou me orientar e foi sempre paciente e solícito, Prof. Dr. Oscar Santos, que demonstrou apoio e compreensão nos momentos mais difíceis, doutoranda Eloíze Alves, que mais que uma co-autora em meu artigo, foi um suporte essencial, me ajudando a enxergar caminhos onde eu não percebia, sem ela não teria sido possível.

## **APRESENTAÇÃO**

Esta dissertação de mestrado está apresentada na forma de um artigo científico.

**Autores:** Gislaine A. S. Ientz, Eloize S.Alves, Matheus Campos Castro, Giovana Frigo, Christyna Beatriz Genovez Tavares, Oscar O. Santos, Jesuí V. Visentainer

**Título do artigo:** Effects of pasteurization and freeze drying on proximal composition, fatty acids composition and lipid quality in colostrum human milk

**Nome da revista para o qual foi submetido:** Journal of the Brazilian Chemical Society

## GENERAL ABSTRACT

### INTRODUCTION.

Human milk is widely known as the ideal form of nutrition for newborns, and its intake is recommended after the first 60 minutes of life, lasting up to two years of age. Its characteristics make it nutritionally superior to commercial infant formulas, making its use paramount especially for neonates under intensive care. The main components of milk are water, carbohydrates, lipids and proteins, which contribute to the gut microbiota and have specific functions in protein and cellular metabolism and immune response. Among these compounds, lipids have functions in the provision of energy, in the transport and absorption of fat-soluble vitamins, in neurological and cerebral development, mainly due to the presence of long-chain polyunsaturated fatty acids, such as docoexanoic acid (DHA), which belongs to the omega-3 family, and araquidonic acid, from the omega-6 family. Human milk has different characteristics according to the lactation phase, according to the needs of babies development stages. The milk obtained from the 1st to the 7th day of lactation is called colostrum, from the 8th to the 14th is transitional, from the 14th day is the mature. Among these, human milk of the colostrum phase plays a great role in immune function, because it is the food offered when neonates have the first contact with the external environment. It also acts therapeutically in the preservation of diseases such as necrotizing enterocolitis, retinopathy, pulmonary broncho dysplasia and sepsis. Despite so many benefits, factors such as neonatal hospitalization, hospitalization and/or maternal death, allergies, preexisting diseases, among others, may compromise the newborns access to breast milk. And in this scenario comes the action of human milk banks, which are considered strategic elements of health public policies. Even so, factors such as low incidence of donation, stability, storage and transportation of the given human milk can also disrupt the supply in milk banks. To minimize the impacts related to the human milk preservation, Holder pasteurization has been widely applied and studies related to freeze-dried have grown, due to the fact that this technology allows the obtaining of milk powder, which facilitates handling, storage and transportation. However, in order to make adequate supplementation in the feeding of newborns, it is important to preserve the components of human milk, regardless of the technological process applied.

### AIMS.

Evaluating the effects of pasteurization and freeze-drying on the proximal composition, fatty acid composition and lipid quality of human milk of the colostrum phase.

### MATERIAL AND METHOD.

This study was conducted in partnership with the Human Milk Bank of the University Hospital of the State University of Maringá, and had approval from the Ethics Council under number 3.430.478/2019. Colostrum human milk samples were collected from 15 different mothers donation, each aliquot containing 100mL that were collected in appropriate glass bottles. The samples were homogenized in a pool and then divided into 4 parts and stored at  $-18^{\circ}\text{C}$ , for subsequent application of different treatments: untreated sample (control), called raw colostrum human milk (RCHM), pasteurized sample, called pasteurized colostrum human milk (PastCHM), pasteurized sample followed by freeze drying, called pasteurized and freeze-dried colostro human milk (PastFdCHM) and freeze dried sample, called freeze-dried colostro human milk (FdCHM). Holder pasteurization was conducted according to Anvisa protocol, subjecting the samples to heating at  $68.4^{\circ}\text{C}$  until the center of the vials reached  $62.5^{\circ}\text{C}$  for 30 minutes, followed by cooling at  $4^{\circ}\text{C}$  and freezing at  $-18^{\circ}\text{C}$ . For freeze drying, the sample was stored at  $-18^{\circ}\text{C}$  for 48h, then submitted to freeze drying at  $-52^{\circ}\text{C}$  and 0.031 bar until constant weight maintenance. For composition, analyses of moisture, ash and proteins were performed, and the amount of carbohydrates was obtained per calculation of difference and the energy value was expressed by the sum of the macronutrients that compose it, with the use of conversion factors of nutrients that potentially provide energy to the human body, such as lipids, carbohydrates and proteins, in which a gram of

carbohydrate and one gram of protein correspond to 4kcal each, and one gram of fat to 9kcal. To evaluate the composition in fatty acids (FA), the methyl steres of fatty acids were prepared by methylation of the total lipids for analysis of composition in FAs. And later analyzed in gas chromatograph (CG, Trace Ultra 3300) with flame ionization detector (FID), the injection mode divided in the proportion of 1: 100 was used. The lipid nutritional quality was calculated by the mean fatty acid composition determined by gas chromatography (n = 3) using six indices: atherogenicity index (AI), thrombogenicity index (TI), hypocholesterolemic/hypercholesterolemic FA ratio (H/H), sum of the fatty acids of the omega-6 family due to the fatty acids of the omega-3 family, sum of eicosatetraenoic fatty acids (EPA) and docosahexaenoic fatty acids (DHA) and finally the sum of FA polyunsaturated due to the sum of saturated FA. All analyses were performed in triplicate and submitted to variance analysis (ANOVA) and Tukey test for their comparisons ( $p < 0.05$ ). The data were also submitted to multivariate principal component analysis (PCA) analysis using Rstudio software. The data were also submitted to multivariate principal component analysis (PCA) analysis using Rstudio software.

### **RESULTADOS E DISCUSSÃO.**

The proximal composition demonstrated the maintenance of lipid content in the different processing, showing no difference of the other components for raw colostrum milk (RCHM) and pasteurized colostrum milk (PastCHM), and presenting difference for ash, proteins, and caloric value for freeze-dried colostrum milk (FdCHM) and pasteurized+freeze-dried colostrum milk (PastFdCHM). This showed that the association of two treatments – pasteurization followed by freeze drying – caused differences at the level of 5% significance for the content of ash, proteins, and caloric value, with no difference in moisture, lipids and carbohydrates, which demonstrates greater need for studies to evaluate the impacts of the use of the two treatments in combination. The fatty acid composition was slightly affected after processing, and 48% of the fatty acids showed no significant difference in the different processes. The fatty acids with the highest prevalence were oleic fatty acids (18:1n-9), followed by palmitic acids (16:0) and linoleic (18:2n-6). It was observed that the application of the treatments showed effects on the concentration of medium-chain fatty acids, such as lauric (12:0), myristic (14:0) and palmitic (16:0), since the treated samples showed a significant difference in relation to RCHM. Despite the changes observed, it is interesting to note that, the sum referring to the fatty acid of the n-6 family, MUFA (monounsaturated fatty acids) and PUFA (polyunsaturated fatty acids) did not present any difference, which points to an important result, because these fatty acids act in the DHA synthesis, an essential component for brain development, constituting one of the reasons why breastfeeding premature babies with breast milk overlaps with the use of infant commercial formulas. In addition, lipid nutritional quality indices were obtained, unpublished for CHM submitted to pasteurization and freeze drying. However, it was observed that there was a significant difference ( $p > 0.05$ ) in the indices of lipid nutritional quality when pasteurization and lyophilization processes were compared to untreated colostrum human milk (RCHM). Thus, it is suggested that the temperature applied in the samples, together with the melting point between the saturation of fatty acids, influences the concentrations identified, in addition to other factors, such as handling conditions. Similar behaviors were observed by PCA for freeze-dried and pasteurized and freeze-dried colostrum human milk.

### **CONCLUSIONS.**

This study demonstrated that there are variations in the proximal composition, in the fatty acid composition and consequently in the lipid quality of human colostrum milk submitted to different conservation treatments (pasteurization, lyophilization or pasteurization combined with lyophilization) when compared to raw colostrum milk.

Regarding the proximal composition, no significant difference was observed between the pasteurized sample and the untreated sample. However, the sample in which there was a combination of pasteurization and lyophilization differed from the sample only lyophilized in relation to the contents of proteins, ash and, consequently, energy value. Lipid content showed no significant difference.

Regarding the composition of fatty acids, of the 31 identified fatty acids, 14 did not present a significant difference between the different treatments, and the sum of FA of the n-6 family, MUFA and PUFA remained preserved. Among the FA influenced by the treatments, the medium chain (12:0, 14:0, 15:0, 16:00) stand out.

The results obtained for lipid nutritional quality are complementary for the evaluation of colostrum human milk, and the sum of the FA ratio of the n-6 and n-3 family did not show difference for the different treatments. For the other aspects there was difference, being interesting its evaluation in other studies.

When applying principal component analysis on the lipid quality of the samples, different behaviors were observed for HMCC and HMCPast samples and similar behavior for HMCfFd and HMCPastFd.

The results suggest that the application of pasteurization and lyophilization processes are adequate from the point of view of maintaining lipids in colostrum human milk, in addition to the prevalence of preserved FA compared to the total identified. However, new investigations must be conducted in view of the complexity of the human milk matrix and the specificities of the processes employed, such as the evaluation of temperatures used in processes and storage.

**Keywords:** fatty acids, lipid quality indices, macronutrients, colostrum human milk.

## RESUMO GERAL

### INTRODUÇÃO.

O leite humano é largamente conhecido como a forma ideal de nutrição para recém nascidos, sendo recomendada sua ingestão após os 60 primeiros minutos de vida, perdurando até dois anos idade. Suas características o tornam nutricionalmente superior a fórmulas infantis comerciais, tornando seu uso primordial especialmente para nenotatos submetidos a cuidados de terapia intensiva. Os principais componentes do leite são água, carboidratos, lipídios e proteínas, que contribuem para a microbiota do intestino e apresentam funções específicas no metabolismo proteico e celular e na resposta imunológica. Dentre estes compostos, os lipídios apresentam funções na provisão de energia, no transporte e absorção de vitaminas lipossolúveis, no desenvolvimento neurológico e cerebral, devido principalmente a presença de ácidos graxos poliinsaturados de cadeia longa, como o ácido docoexanoico (DHA), que pertence à família ômega-3, e ácido araquidônico, da família ômega-6. O leite humano tem características diferentes de acordo com a fase de lactação, de forma que os aspectos apresentados acompanham as necessidades das etapas de desenvolvimento dos bebês. O leite obtido do 1º ao 7º dia de lactação recebe o nome de colostro, do 8º ao 14º é o transicional, e a partir do 14º dia tem-se o leite maduro. Dentre estes, o leite humano da fase colostro tem grande papel na função imunológica, por ser o alimento oferecido quando os neonatos tem o primeiro contato com o ambiente externo. Também atua de forma terapêutica na prevenção de doenças como enterocolite necrosante, retinopatia, displasia bronco pulmonar e sepse. Apesar de tantos benefícios, fatores como hospitalização neonatal, hospitalização e/ou morte materna, alergias, doenças preexistentes, entre outros, podem comprometer o acesso dos recém-nascidos ao leite materno. E neste cenário entra a ação dos bancos de leite humano, que são considerados elementos estratégicos de políticas públicas para a saúde. Mesmo assim, fatores como baixa incidência de doação, estabilidade, armazenamento e transporte do leite humano doado também podem interromper a oferta nos bancos de leite. Para minimizar os impactos ligados à preservação do leite humano, tem sido amplamente aplicada a pasteurização Holder e tem crescido os estudos relacionados à liofilização, pelo fato desta tecnologia permitir obtenção do leite em pó, o que facilita o manuseio, o armazenamento e o transporte. Todavia, para que seja feita a suplementação adequada na alimentação dos recém-nascidos, é importante que haja a preservação dos componentes do leite humano, independente do processo tecnológico aplicado.

### OBJETIVOS.

Avaliar os efeitos da pasteurização e da liofilização sobre a composição proximal, composição em ácidos graxos e qualidade lipídica do leite humano da fase colostro.

### MATERIAL E METÓDOS.

Este estudo foi realizado em parceria com o Banco de Leite Humano do Hospital Universitário da Universidade Estadual de Maringá, e teve aprovação do Conselho de Ética sob número 3.430.478/2019. Foram coletadas amostras de leite humano colostro provenientes da doação de 15 mães distintas, cada alíquota contendo 100mL que foram coletados em frascos de vidro adequados. As amostras foram homogeneizadas em um *pool* e posteriormente divididas em 4 partes e armazenadas a -18°C para posterior aplicação de diferentes tratamentos: amostra sem tratamento (controle), denominada leite humano colostro cru (LHCC), amostra pasteurizada, denominada leite humano colostro pasteurizado, amostra pasteurizada seguida de liofilização, denominada leite humano colostro pasteurizado e liofilizado (LHCPL) e amostra liofilizada, denominada leite humano colostro liofilizado (LHCL). A pasteurização Holder foi conduzida conforme protocolo da Anvisa, submetendo as amostras a aquecimento a 68,4°C até que o centro dos frascos atingisse 62,5°C por 30 minutos, seguido de resfriamento a 4°C e congelamento a -18°C. Para liofilização, a amostra foi armazenada a -18°C por 48h, em seguida submetida a liofilização a -52°C e 0,031 bar até manutenção de peso constante. Para composição foram realizadas análises de umidade, cinzas e proteínas, e foi obtido a quantidade de carboidratos por cálculo de diferença e o valor energético do alimento foi expresso pela soma dos macronutrientes

que o compõem, com o uso de fatores de conversão de nutrientes que potencialmente fornecem energia para o corpo humano, como lipídios, carboidratos e proteínas, em que uma grama de carboidrato e uma grama de proteína correspondem a 4kcal cada, e uma grama de gordura a 9kcal. Para avaliação da composição em ácidos graxos os ésteres metílicos de ácidos graxos (AG) foram preparados por metilação dos lipídios totais para análise de composição em AG. E posteriormente analisado em cromatógrafo gasoso (CG, Trace Ultra 3300) com detector de ionização de chama (DIC), foi utilizado o modo de injeção dividida na proporção de 1: 100. A qualidade nutricional lipídica foi calculada pela média da composição de ácidos graxos determinada por cromatografia gasosa (n = 3) utilizando seis índices: índice de aterogenicidade (IA) , índice de trombogênicidade (IT), razão de AG hipocolesterolêmicos/hipercolesterolêmicos (H/H), soma dos ácidos graxos da família ômega-6 em razão dos ácidos graxos da família ômega-3, soma dos ácidos graxos eicosapentaenóicos (EPA) e ácidos graxos docosahexaenóicos (DHA) e, por fim, a soma dos AG poliinsaturados em razão da soma dos AG saturados. Todas as análises foram realizadas em triplicata e submetidas à análise de variância (ANOVA) e teste de Tukey para suas comparações (p < 0,05). Os dados ainda foram submetidos à exploração multivariada de análise de componentes principais (PCA), empregando Rstudio software.

### **RESULTADOS E DISCUSSÃO.**

A composição proximal demonstrou a manutenção do conteúdo de lipídios nos diferentes processamentos, não apresentando diferença dos demais componentes para as amostras de leite colostro cru (LHCC) e leite colostro pasteurizado (LHCP) e apresentando diferença para cinzas, proteínas e valor calórico para as amostras de leite colostro cru+liofilizado (LHCL) e leite colostro pasteurizado+liofilizado (LHCPL). Isso demonstrou que a associação de dois tratamentos – pasteurização seguida de liofilização – provocou diferenças ao nível de 5% de significância para o teor de minerais, proteínas, e valor calórico, não tendo sido observado diferença para umidade, lipídios e carboidratos, o que demonstra maior necessidade de estudos para avaliar os impactos do emprego dos dois tratamentos de forma combinada. A composição em ácidos graxos foi ligeiramente afetada após os processamentos, sendo que 48% dos ácidos graxos não apresentaram diferença significativa nos diferentes processos. O ácido graxo de maior predominância foi ácido graxo oleico (18:1n-9), seguido do palmítico (16:0) e linoleico (18:2n-6). Observou-se que a aplicação dos tratamentos apresentou efeitos na concentração dos ácidos graxos de cadeia média, como láurico (12:0), mirístico (14:0) e palmítico (16:0), uma vez que as amostras tratadas apresentaram diferença significativa em relação ao LHMCC. Apesar das alterações observadas, é interessante ressaltar que o somatório referente aos AG da família n-6, dos MUFA (ácidos graxos monoinsaturados) e dos PUFA (ácidos graxos poliinsaturados) não apresentaram diferença, o que aponta um resultado importante pois estes AG atuam na síntese do DHA, componente essencial para o desenvolvimento cerebral, constituindo um dos motivos pelos quais a amamentação de bebês prematuros com leite materno se sobrepõe ao uso de fórmulas comerciais infantis. Ainda, obteve-se índices de qualidade nutricional lipídica, sendo estes inéditos para o HMC submetido a pasteurização e liofilização. Porém observou-se que houve diferença significativa (p > 0.05) nos índices de qualidade nutricional lipídica quando comparados os processos de pasteurização e liofilização ao leite humano colostro não tratado (LHCC). Desta forma sugere-se que a temperatura aplicada nas amostras, em conjunto com o ponto de fusão entre a saturação dos ácidos graxos, influenciam nas concentrações identificadas além de outros fatores como as condições de manuseio. Pelo PCA foram observados comportamentos similares para leite colostro liofilizado e pasteurizado liofilizado.

### **CONCLUSÕES.**

Este estudo demonstrou haver variações na composição proximal, na composição de ácidos graxos e conseqüentemente na qualidade lipídica do leite humano colostro submetido a diferentes tratamentos de conservação (pasteurização, liofilização ou pasteurização combinada à liofilização) quando comparado ao leite colostro cru.

Em relação à composição proximal, não foi observada diferença significativa entre a amostra pasteurizada e amostra sem tratamento. Porém a amostra em que houve combinação de

pasteurização e liofilização diferiu da amostra apenas liofilizada em relação aos conteúdos de proteínas, cinzas e conseqüentemente valor energético. O conteúdo lipídico não apresentou diferença significativa.

Em relação à composição de ácidos graxos, dos 31 ácidos graxos identificados, 14 não apresentaram diferença significativa entre os diferentes tratamentos, sendo que o somatório de AG da família n-6, MUFA e PUFA permaneceu preservado. Dentre os AG influenciados pelos tratamentos destacam-se os de cadeia média (12:0, 14:0, 15:0, 16:00).

Os resultados obtidos para qualidade nutricional lipídica são inéditos para avaliação de leite humano colostro, sendo que o somatório da razão de AG da família n-6 e n-3 não apresentou diferença para os diferentes tratamentos. Para os demais aspectos houve diferença, sendo interessante sua avaliação em outros estudos.

Ao aplicar a análise de componentes principais sobre a qualidade lipídica das amostras, observou-se comportamentos distintos para as amostras de LHCC e LHCP e similares para LHCL e LHCPL.


Os resultados sugerem que a aplicação de processos de pasteurização e liofilização são adequados do ponto de vista de manutenção dos lipídios no leite humano colostro, além da prevalência de AG preservados em comparação ao total identificado. Contudo, novas investigações devem ser conduzidas tendo em vista a complexidade da matriz de leite humano e das especificidades dos processos empregados, como a avaliação das temperaturas empregadas nos processos e no armazenamento.

**Palavras chaves:** ácidos graxos, cromatografia gasosa, índices, macronutrientes, leite humano colostro.

# ARTICLE

## Effects of pasteurization and freeze drying on proximal composition, fatty acids composition and lipid quality in colostrum human milk

### Graphical Abstract (GA)



**Effects of Pasteurization and Freeze Drying on Proximal Composition, Fatty Acids  
Composition and Lipid Quality in Colostrum Human Milk**

*Gislaine A. S. Ientz,<sup>a</sup> Eloíze S. Alves,<sup>a</sup> Matheus C. Castro,<sup>b</sup> Giovana Frigo,<sup>a</sup> Christyna B. G.  
Tavares,<sup>c</sup> Jeane E. L. Visentainer,<sup>c</sup> Oscar O. Santos<sup>b</sup> and Jesuí V. Visentainer <sup>\*a,b</sup>*

*<sup>a</sup>Programa de Pós-Graduação em Ciência de Alimentos, Universidade Estadual de Maringá, Av.  
Colombo 5790, 87020-900, Maringá, Paraná, Brasil*

*<sup>b</sup>Departamento de Química, Universidade Estadual de Maringá, Av. Colombo 5790, 87020-900  
Maringá, Paraná, Brasil*

*<sup>c</sup>Programa de Pós-Graduação em Biociências e Saúde, Av. Colombo 5790, Maringá, 87020-900  
Paraná, Brasil*

Affiliations: APLE-A – Analítica Aplicada a Lipídios, Esteróis e Antioxidantes, Universidade Estadual de Maringá.

**\*Jesuí Vergílio Visentainer, PhD**

E-mail: jesuivv@gmail.com

ORCID ID: <https://orcid.org/0000-0003-3412-897X>

**Abstract**

Colostrum human milk samples obtained from human milk banks received different treatments and were evaluated for their proximal composition, fatty acids composition and lipid quality. The total lipids content was maintained in the treatments. There was no difference in moisture, ash, total proteins, carbohydrates and energetic value for raw colostrum human milk and pasteurized colostrum human milk, and there was difference in ash, total proteins and energetic value for freeze-dried colostrum human milk and pasteurized + freeze-dried colostrum human milk. The fatty acids composition demonstrated no difference in the processes for 14 of 31 fatty acids identified. Furthermore, lipid quality indices were obtained, which were unpublished for colostrum human milk submitted to pasteurization and freeze drying. Principal component analysis showed similar behaviors for freeze-dried colostrum human milk and pasteurized and freeze-dried colostrum human milk. So, the processes used may be promising for application in colostrum human milk, due to the maintenance of its proximal characteristics and fatty acid composition.

**Keywords:** fatty acids, lipid quality indices, macronutrients, colostrum human milk.

## Introduction

Human milk (HM) is widely known as the ideal newborn nutrition, for presenting benefits until the adulthood.<sup>1</sup> Besides offering the necessary contents for child demand, it is a source of components deficient in commercial products, which makes its use excellent for preterm babies or under intensive care.<sup>2</sup>

In general, HM is mostly composed of water (about 90% of the total), followed by carbohydrates, lipids and proteins.<sup>3,4</sup> In addition to nutrition benefits, HM contributes to the increase of the intestine's beneficial microbiota and to specific functions in protein and cellular metabolism and immune response.<sup>4</sup>

Among these compounds, the lipids present important functions for newborns, as energy source, and transport and absorption of fat-soluble vitamins. And there are evidence of their action on brain, neurological, and immunological development, due to the long-chain polyunsaturated fatty acids, such as the docosahexanoic acid (DHA, 22:6n-3), from the omega-3 family (n-3), and arachidonic acid (ARA, 24n-6) from the omega-6 family (n-6).<sup>3-5</sup> In addition, there is the possibility of future disease management through the lipid quality evaluation.<sup>6</sup> Lipids are present in HM in a fat globule form, and triacylglycerol is formed in the endoplasmic reticulum from circulating fatty acids (FAs) or synthesized in epithelial cells from glucose.<sup>7,8</sup>

According to the maternal lactation phase, the HM presents variations in its physical-chemical characteristics, proximal composition, and immunological functions. The classification in the different lactation phases is colostrum (from the 1st to the 7th day), transitional (8th to 14th day) and mature (from the 15th day). This variation follows the child's development, giving adequate nutritional aspects to each growing step.<sup>9,10</sup>

Originally, colostrum human milk (CHM) presents a great role in immunological functions, due to the newborn first contact with the external environment.<sup>11</sup> Its complex composition, besides acting in the nutritional function of newborns, presents therapeutic characteristics, preventing diseases such as necrotizing enterocolitis, retinopathy, pulmonary broncho dysplasia, and sepsis. For all these benefits, the exclusive breastfeeding is recommended

from 60 min of life until two years old.<sup>9</sup>

However, different factors can compromise HM access, such as neonatal hospitalization, pre-existing diseases, nutritional disorders, maternal death, and low production, among others.<sup>12</sup> In these cases, HM from human milk banks are a possibility for consumption, making them a strategic element of breastfeeding public policy.<sup>13</sup> Nevertheless, the availability of HM in human milk banks may be compromised by the donation incidence, stability, storage, and transportation. For these reasons, ways have been studied to ensure the safety and prolong the shelf life of raw HM, such as pasteurization and recently freeze drying.<sup>3,5</sup> Pasteurization is the most common process used in human milk banks. But the potential use of freeze-drying to provide HM has caused the growth of its study, because this technology, which consists of sublimation dehydration, allows the obtaining of powdered HM, which facilitates handling, storage, and transport.<sup>9</sup>

To achieve better HM compounds preservation, it is important studying its macronutrients according to the treatments employed, because the evaluation of particularities of HM composition in each lactation phase can aim a feeding supplemented according to the needs of the preterm life stage under hospitalization.<sup>14</sup> Thus, the information about the proximal composition, FA composition and nutritional indices of lipid quality of CHM are important, because characterizing the lipid quality of the diet that can serve as a basis for administration in the first stage of life.

In this context, the purpose of this study was to evaluate the proximal composition, FAs composition and lipid quality of CHM under different treatments (pasteurization and/or freeze drying), comparing them to raw CHM, to observe their effects on the aspects mentioned.

## **Experimental**

### **Reagents**

Reagents for lipid extraction: High performance liquid chromatography grade methanol and chloroform purchased from J.T. Baker® (Philipsburg, USA) and Riedel-de Haën (Seelze,

Lower Saxony, Germany) were used. For esterification, chloroform, n-heptane, methanol, potassium hydroxide and sodium chloride were used, all with a high degree of purity > 99%, purchased from Synth (São Paulo, Brazil). For the realization of gas chromatography analysis, reference standard fatty acid methyl esters (FAME) FAME Mix, unsaturated C4-C24 ( $\geq 97\%$ ) was purchased from SigmaAldrich (Saint Louis, USA).

### **Ethical Approval and Sampling**

The present study has a partnership with the Human Milk Bank of the Regional Hospital of Maringá (HMB), and was approved by the Ethics Committee of the State University of Maringá under number 3.430.478/2019.

Colostrum human milk was collected from the donation of 15 different mothers provided by the Human Milk Bank of the Regional Hospital of Maringá. Each aliquot containing 100mL was collected in glass bottles and identified as mother 1, mother 2, up to mother 15. Subsequently, they were homogenized in a pool with a total of 1.5L. From this pool, four aliquots with 375mL were separated and stored at  $-18^{\circ}\text{C}$ , for subsequent use of treatment.

### **Treatments employed**

The four aliquots of CHM were identified according to the treatment received.


(i) Raw colostrum human milk (RCHM): sample not subjected to treatment, sent to storage at  $-18^{\circ}\text{C}$ ;

(ii) Pasteurized colostrum human milk (PastCHM): colostrum human milk sample submitted to pasteurization;

(iii) Freeze-dried colostrum human milk raw (FdCHM): raw colostrum human milk sample submitted directly to freeze-drying;

(iv) Pasteurized + freeze-dried colostrum human milk (PastFdCHM): sample of pasteurized and subsequently freeze-dried colostrum human milk.

Figure 1 shows the sample segmentation.



**Figure 1.** Samples segmentation and identification according to treatment received.

## Application of treatments

### Control

Approximately 375mL of RCHM was kept as a control sample (untreated), without application of treatment and evaluated in the following steps in a liquid state, called RCHM. The sample was stored in a glass bottle with a suitable screw cap.

### Holder Pasteurization

The application of Holder pasteurization occurred according to Anvisa protocol: <sup>15</sup> 375mL of human milk colostrum contained in a glass bottle was submitted to a water bath (SL-152 Ultra-thermostated Digital Refrigerated Bath, Solab Cientifica, Brazil). The thermal treatment lasted for 30 minutes after reaching a temperature of 62.5 °C in the center of the bottle, manual agitation was also provoked every 5 minutes. The water bath temperature was maintained

at 68.4 °C. Next, the bottle was immersed in a water bath containing ice until it reached 4 °C, and then frozen at -18 °C until other steps.

### **Freeze-Drying**

First, the appropriate container containing 375mL of CHM was stored for 48h at -18°C. Then, lyophilization was performed according to Manin *et al.*,<sup>3</sup> where the freeze-drying processing application was submitted in a freeze-dryer (Alpha 1-2 LD Plus, model 101522, Osterode, Germany) at about -52 °C and 0.031 mbar. The lyophilization time was maintained until a constant weight of the samples was obtained.

### **Holder pasteurization followed by freeze-drying**

Preliminarily, 375mL of stored colostrum human milk were conducted to heat treatment by Holder pasteurization as mentioned above.<sup>15</sup> Afterwards, the pasteurized sample was frozen at -18 °C for 48 hours in preparation for the lyophilization process. Then, it was submitted to drying with the same previously mentioned parameters.<sup>3</sup> It is worth mentioning that the freeze-drying time was maintained for approximately 48 h, when a constant weight was obtained for the samples on an analytical balance.

### **Proximal composition**

The analysis of protein (method 990.03), moisture (method 934.01), ash (method 942.05), and carbohydrates (calculated by difference), were made according to official methods of analysis of the Association of Official Analytical Chemists (AOAC).<sup>16</sup> There was also the determination of the lipid content.<sup>17</sup> The energy value of the food was expressed by the sum of the macronutrients that compose it, using nutrient conversion factors that potentially provide energy for the human body, such as total lipids, carbohydrates and proteins, in which 1 g of carbohydrate and 1 g of protein correspond to 4 kcal each, and 1 g of fat to 9 kcal.<sup>18</sup>

Total lipids from all samples were extracted according to Folch *et al.*,<sup>17</sup> fatty acid methyl

esters (FAMES) were prepared by the methylation indicated in International Organization for Standardization (ISO) N° 15885: 2000.<sup>19</sup> The upper phase obtained was collected, stored in an appropriate vial, and then analyzed on a gas chromatograph (GC) (Trace Ultra 3300, Waltham, USA) with a flame ionization detector (FID), CP-7420 capillary column (100.0 m in size, 0.25 mm inside diameter and 0.25  $\mu\text{m}$  thin film of cyanopropyl as stationary phase) and split/split less injector. The flows used for separation were 1.4  $\text{mL min}^{-1}$  for hydrogen ( $\text{H}_2$ ) carrier gas, 30  $\text{mL min}^{-1}$  for nitrogen ( $\text{N}_2$ ) make-up gas, and 30 and 300  $\text{mL min}^{-1}$  for the flame gases ( $\text{H}_2$  and synthetic air, respectively). The GC-FID oven was programmed to 65  $^\circ\text{C}$  and held for 4 min, then heated to 185  $^\circ\text{C}$  to 16  $^\circ\text{C min}^{-1}$  and held for 12 min, then heated to 235  $^\circ\text{C}$  to 20  $^\circ\text{C min}^{-1}$  and held for 9 min. The detector and injector temperatures were at 250 and 230  $^\circ\text{C}$ , respectively. Split injection mode was used with a ratio of 1:100 and the volume of sample injections was 2.0  $\mu\text{L}$ . The FAMES were identified by comparing the retention times of the sample's constituents with the analytical standards (FAME standard mixture, C4-C24, Saint Louis, Sigma-Aldrich). Peak areas were determined using LabSolutions software and composition in FA were expressed % relative area. All samples were analyzed in triplicate.

### **Lipid nutritional quality of human milk**

The lipid nutritional quality was calculated by the average composition of fatty acids determined by gas chromatography ( $n = 3$ ) according to the following equations, using the six indices: atherogenicity index (AI) (equation 1), thrombogenicity index (TI) (equation 2)<sup>20</sup>, and the hypocholesterolemic/hypercholesterolemic (H/H) fatty acids ratio (equation 3)<sup>21</sup>, in addition to the sum of the fatty acids of the omega-6 family in relation to the fatty acids of the omega-3 family (equation 4)<sup>22</sup>, the sum of fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) (equation 5); and finally, the sum of the polyunsaturated fatty acids due to the sum of the saturated fatty acids (equation 6).<sup>23</sup> The equations are shown below:

$$AI = \frac{[12:0 + (4 \times 14:0) + 16:0]}{MUFA + n6 + n3} \quad \text{Equation (1)}$$

$$TI = \frac{(14:0 + 16:0 + 18:0)}{[(0.5 \times MUFA) + (0.5 \times n6) + (3 \times n3) + (\frac{n3}{n6})]} \quad \text{Equation (2)}$$

$$HH = \frac{[(18:1n - 9 + 18:2n - 6 + 18:3n - 3 + 20:3n - 6 + 20:4n - 6 + 20:5n - 3 + 22:6n - 3)]}{(12:0 + 14:0 + 16:0)} \quad \text{Equation (3)}$$

$$\text{Omega family proportion} = \frac{\Sigma[n6]}{\Sigma[n3]} \quad \text{Equation (4)}$$

$$\text{Sum of essential fatty acids} = \text{EPA} + \text{DHA} \quad \text{Equation (5)}$$

*Proportion of polyunsaturated and saturated fatty acids*

$$= \frac{\Sigma[PUFAs]}{\Sigma[SFAAs]} \quad \text{Equation (6)}$$

Where OFP is omega family proportion, SEFA is the sum of the essential fatty acids EPA and DHA; and MUFA is monounsaturated fatty acids.

### **Statistical analysis**

The averages of triplicates of all analyzes were submitted to analysis of variance (ANOVA) and Tukey's test for their comparisons ( $p < 0.05$ ), using the Statistica software version 7.0.<sup>24</sup> The data obtained regarding lipid quality were subsequently submitted to multivariate principal component analysis (PCA) exploration using the software previously mentioned.

## Results and Discussion

### Proximal composition

The proximal composition (moisture, ash, total protein, total lipids and carbohydrates), in g per 100 g, and the energy value, in kcal per 100 g of sample, of the RCHM and PastCHM (liquid samples) are exhibited in Table 1. There was no significant difference in moisture, ash, total proteins, total lipids, carbohydrates, and energetic value between RCHM and PastCHM. These results indicate that pasteurization did not impact the PastCHM proximal composition when compared to RCHM, and are similar to those obtained by Santos et al.,<sup>25</sup> that found difference only for lipids content when compared CHM pasteurized and raw, and observed maintenance for moisture, ash, total proteins, carbohydrates and energetic value.<sup>25</sup>

**Table 1.** Proximal composition and energy value of RCHM and PastCHM

|  | Sample                      |                             |
|--|-----------------------------|-----------------------------|
|  | RCHM                        | PastCHM                     |
| Moisture / (g per 100 g)                     | 88.720 ± 0.203 <sup>a</sup> | 88.417 ± 0.115 <sup>a</sup> |
| Ash / (g per 100 g)                          | 0.377 ± 0.012 <sup>a</sup>  | 0.363 ± 0.018 <sup>a</sup>  |
| Total proteins / (g per 100 g)               | 2.190 ± 0.087 <sup>a</sup>  | 2.080 ± 0.112 <sup>a</sup>  |
| Total lipids / (g per 100 g)                 | 2.357 ± 0.055 <sup>a</sup>  | 3.141 ± 0.694 <sup>a</sup>  |
| Carbohydrates / (g per 100 g)                | 6.357 ± 0.243 <sup>a</sup>  | 6.000 ± 0.512 <sup>a</sup>  |
| Energetic value / (kcal per 100 g of sample) | 55.397 ± 0.550 <sup>a</sup> | 60.588 ± 3.788 <sup>a</sup> |

Results expressed as mean ± standard deviation of triplicate. Values with different letters on the same line are significantly different ( $p < 0.05$ ) by Tukey's test. RCHM: raw colostrum human milk; PastCHM: pasteurized colostrum human milk.

Table 2 presents the composition (g per 100 g) and the energy value (kcal per 100 g of sample) of the FdCHM and PastFdCHM (solid samples).

**Table 2.** Proximal composition and energy value of FdCHM and PastFdCHM

|  | Sample                       |                              |
|--|------------------------------|------------------------------|
|  | FdCHM                        | PastFdCHM                    |
| Moisture / (g per 100 g)                     | 4.287 ± 0.117 <sup>a</sup>   | 3.840 ± 0.356 <sup>a</sup>   |
| Ash / (g per 100 g)                          | 3.103 ± 0.308 <sup>a</sup>   | 2.487 ± 0.137 <sup>b</sup>   |
| Total proteins / (g per 100 g)               | 19.190 ± 1.082 <sup>a</sup>  | 16.500 ± 1.154 <sup>b</sup>  |
| Total lipids / (g per 100 g)                 | 18.330 ± 0.590 <sup>a</sup>  | 20.790 ± 1.467 <sup>a</sup>  |
| Carbohydrates / (g per 100 g)                | 55.090 ± 1.102 <sup>a</sup>  | 56.383 ± 1.555 <sup>a</sup>  |
| Energetic value / (kcal per 100 g of sample) | 462.094 ± 4.061 <sup>b</sup> | 478.643 ± 9.225 <sup>a</sup> |

Results expressed as mean ± standard deviation of triplicate. Values with different letters on the same line are significantly different ( $p < 0.05$ ) by Tukey's test. FdCHM: freeze dried colostrum human milk; PastFdCHM: pasteurized and freeze-dried colostrum human milk.

According to Table 2, the sample submitted to pasteurization followed by freeze-drying (PastFdCHM) presented differences at the level of 5% significance in ash and total protein when compared to the sample submitted to freeze drying without previous pasteurization (FdCHM). These results can be related to the fact that the two processes use temperatures in distinct ranges may have caused mineral degradation and protein decrease.<sup>26</sup> More than 400 proteins are present on HM, and they are divided into whey proteins (60-80%), caseins (20- 40%) and milk fat globule membrane proteins (1-4%).<sup>4</sup> Meng et al.<sup>4</sup> related in their review that some whey proteins, as  $\alpha$ -lactalbumin and lactoferrin present heat resistance and decreasing levels at freezing at - 20 °C, but it was not found reports about heating or freezing influence on caseins. In another hand, cooling causes  $\beta$ -casein dissociation and decrease, so they concluded that there is a gap on knowledge about properties of HM proteins. Another factor to note is that the PastFdCHM sample was submitted a higher number of handling cycles compared to the FdCHM sample, which may also have implied changes in the total protein content.

Once that energetic value is obtained by calculation using the amount of nutrients, its value also presented difference. It is important to observe that FdCHM sample presented a value less than PastFdCHM, related to the fact that PastFdCHM presented a higher value in lipids

content, the nutrient that presents more contribution to energetic value (9 kcal *per* gram of lipid).<sup>18</sup> No difference was observed for moisture, lipids, and carbohydrates. It demonstrates the greater need for studies to evaluate the impacts of the use of the two treatments in a combined way.

### **Fatty acid composition**

Thirty-one FAs were identified using GC-FID (Table 3). The omega system was used to describe FA from omega-3, omega-6 and omega-9 family, in which the letter n followed by a number refers to the position of the double bond, starting the counting of carbons from the methyl group. The results are expressed in percentage of relative area. The columns show the results according to the treatment applied on the samples. The FAs identified are divided into about 50% SFAs, 25% monounsaturated fatty acid (MUFAs), and 25% PUFAs, values similar to those mentioned by Schipper,<sup>27</sup> which indicates 50% SFAs and 20% PUFAs. The prevalent FA was oleic acid (OA, 18:1n-9), followed by palmitic acid (PA, 16:0) and linoleic acid (LA, 18:2n-6). Published data<sup>28-30</sup> show similarities in the total content of FAs found for the colostrum lactation phase.

**Table 3.** Fatty acids composition (relative area percentage) of CHM for each treatment received

| Fatty acids / %                    | Sample                      |                             |                             |                             |
|------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                    | RCHM                        | PastCHM                     | FdCHM                       | PastFdCHM                   |
| 4:0                                | 0.156 ± 0.014 <sup>ab</sup> | 0.132 ± 0.010 <sup>b</sup>  | 0.195 ± 0.037 <sup>a</sup>  | 0.200 ± 0.044 <sup>ab</sup> |
| 6:0                                | 0.547 ± 0.082 <sup>a</sup>  | 0.418 ± 0.027 <sup>a</sup>  | 0.611 ± 0.106 <sup>a</sup>  | 0.620 ± 0.079 <sup>a</sup>  |
| 8:0                                | 0.081 ± 0.011 <sup>a</sup>  | 0.055 ± 0.020 <sup>a</sup>  | 0.072 ± 0.008 <sup>a</sup>  | 0.057 ± 0.006 <sup>a</sup>  |
| 10:0                               | 0.137 ± 0.044 <sup>a</sup>  | 0.096 ± 0.036 <sup>ab</sup> | 0.049 ± 0.010 <sup>b</sup>  | 0.055 ± 0.004 <sup>ab</sup> |
| 12:0 (LAU)                         | 2.322 ± 0.226 <sup>a</sup>  | 0.896 ± 0.038 <sup>b</sup>  | 1.050 ± 0.021 <sup>b</sup>  | 1.011 ± 0.042 <sup>b</sup>  |
| 14:0 (MYR)                         | 5.487 ± 0.316 <sup>a</sup>  | 3.395 ± 0.127 <sup>b</sup>  | 3.771 ± 0.076 <sup>b</sup>  | 3.567 ± 0.089 <sup>b</sup>  |
| 14:1n-9                            | 0.031 ± 0.005 <sup>a</sup>  | 0.042 ± 0.021 <sup>a</sup>  | 0.027 ± 0.001 <sup>a</sup>  | 0.027 ± 0.006 <sup>a</sup>  |
| 15:0                               | 0.192 ± 0.006 <sup>a</sup>  | 0.159 ± 0.020 <sup>b</sup>  | 0.165 ± 0.003 <sup>ab</sup> | 0.160 ± 0.006 <sup>b</sup>  |
| 15:1n-9                            | 0.051 ± 0.026 <sup>a</sup>  | 0.038 ± 0.002 <sup>a</sup>  | 0.034 ± 0.003 <sup>a</sup>  | 0.031 ± 0.007 <sup>a</sup>  |
| 16:0 (PA)                          | 30.822 ± 1.109 <sup>a</sup> | 27.342 ± 0.586 <sup>b</sup> | 27.662 ± 0.315 <sup>b</sup> | 27.241 ± 0.177 <sup>b</sup> |
| 16:1n-7                            | 0.101 ± 0.020 <sup>a</sup>  | 0.141 ± 0.007 <sup>a</sup>  | 0.119 ± 0.024 <sup>a</sup>  | 0.109 ± 0.017 <sup>a</sup>  |
| 16:1n-9                            | 1.078 ± 0.066 <sup>b</sup>  | 1.211 ± 0.065 <sup>b</sup>  | 1.188 ± 0.035 <sup>b</sup>  | 1.314 ± 0.203 <sup>a</sup>  |
| 17:0                               | 0.252 ± 0.032 <sup>a</sup>  | 0.277 ± 0.061 <sup>a</sup>  | 0.301 ± 0.011 <sup>a</sup>  | 0.322 ± 0.013 <sup>a</sup>  |
| 17:1n-9                            | 0.091 ± 0.011 <sup>b</sup>  | 0.119 ± 0.004 <sup>a</sup>  | 0.110 ± 0.011 <sup>ab</sup> | 0.116 ± 0.015 <sup>ab</sup> |
| 18:0                               | 6.525 ± 0.256 <sup>a</sup>  | 7.147 ± 0.354 <sup>a</sup>  | 6.852 ± 0.137 <sup>a</sup>  | 6.928 ± 0.086 <sup>a</sup>  |
| 18:1n-9 (OA)                       | 34.966 ± 4.018 <sup>a</sup> | 38.622 ± 0.824 <sup>a</sup> | 38.364 ± 0.054 <sup>a</sup> | 38.490 ± 0.658 <sup>a</sup> |
| 18:2n-6 (LA)                       | 14.026 ± 2.005 <sup>a</sup> | 15.769 ± 0.493 <sup>a</sup> | 15.269 ± 0.657 <sup>a</sup> | 15.644 ± 0.720 <sup>a</sup> |
| CLA; <i>cis</i> 9, <i>trans</i> 11 | 0.033 ± 0.005 <sup>a</sup>  | 0.043 ± 0.009 <sup>a</sup>  | 0.041 ± 0.010 <sup>a</sup>  | 0.019 ± 0.006 <sup>a</sup>  |
| CLA; <i>trans</i> 10,C12           | 0.051 ± 0.004 <sup>b</sup>  | 0.090 ± 0.005 <sup>a</sup>  | 0.086 ± 0.003 <sup>a</sup>  | 0.110 ± 0.021 <sup>a</sup>  |
| 18:3n-3 (LNA)                      | 0.600 ± 0.008 <sup>a</sup>  | 0.564 ± 0.031 <sup>a</sup>  | 0.595 ± 0.001 <sup>a</sup>  | 0.597 ± 0.045 <sup>a</sup>  |
| 18:3n-6 (GLA)                      | 0.078 ± 0.004 <sup>a</sup>  | 0.100 ± 0.009 <sup>a</sup>  | 0.089 ± 0.011 <sup>a</sup>  | 0.098 ± 0.011 <sup>a</sup>  |
| 20:0                               | 0.090 ± 0.009 <sup>b</sup>  | 0.127 ± 0.023 <sup>ab</sup> | 0.132 ± 0.015 <sup>a</sup>  | 0.109 ± 0.011 <sup>ab</sup> |
| 20:1n-9                            | 0.254 ± 0.019 <sup>b</sup>  | 0.395 ± 0.007 <sup>a</sup>  | 0.435 ± 0.010 <sup>b</sup>  | 0.371 ± 0.058 <sup>a</sup>  |
| 21:0 (HEN)                         | 0.683 ± 0.018 <sup>b</sup>  | 0.897 ± 0.024 <sup>a</sup>  | 0.874 ± 0.008 <sup>a</sup>  | 0.861 ± 0.038 <sup>a</sup>  |
| 20:3n-6                            | 0.367 ± 0.021 <sup>b</sup>  | 0.530 ± 0.007 <sup>a</sup>  | 0.497 ± 0.021 <sup>b</sup>  | 0.484 ± 0.025 <sup>b</sup>  |
| 20:3n-3 (DLA)                      | 0.356 ± 0.019 <sup>b</sup>  | 0.486 ± 0.008 <sup>a</sup>  | 0.449 ± 0.013 <sup>a</sup>  | 0.464 ± 0.030 <sup>a</sup>  |
| 20:4n-6 (ARA)                      | 0.126 ± 0.029 <sup>a</sup>  | 0.170 ± 0.034 <sup>a</sup>  | 0.147 ± 0.024 <sup>a</sup>  | 0.169 ± 0.026 <sup>a</sup>  |
| 22:0                               | 0.054 ± 0.007 <sup>a</sup>  | 0.072 ± 0.009 <sup>a</sup>  | 0.065 ± 0.011 <sup>a</sup>  | 0.072 ± 0.007 <sup>a</sup>  |
| 20:5n-3 (EPA)                      | 0.067 ± 0.007 <sup>b</sup>  | 0.098 ± 0.021 <sup>b</sup>  | 0.225 ± 0.070 <sup>a</sup>  | 0.093 ± 0.019 <sup>b</sup>  |
| 24:0 (LIG)                         | 0.191 ± 0.011 <sup>c</sup>  | 0.334 ± 0.011 <sup>a</sup>  | 0.297 ± 0.012 <sup>b</sup>  | 0.300 ± 0.013 <sup>b</sup>  |
| 24:1n-9                            | 0.061 ± 0.006 <sup>b</sup>  | 0.102 ± 0.009 <sup>a</sup>  | 0.100 ± 0.005 <sup>b</sup>  | 0.093 ± 0.011 <sup>b</sup>  |
| 22:6n-3 (DHA)                      | 0.135 ± 0.008 <sup>a</sup>  | 0.133 ± 0.013 <sup>a</sup>  | 0.130 ± 0.004 <sup>a</sup>  | 0.134 ± 0.006 <sup>a</sup>  |
| Σ (n-3)                            | 1.158 ± 0.015 <sup>b</sup>  | 1.281 ± 0.012 <sup>ab</sup> | 1.398 ± 0.084 <sup>a</sup>  | 1.288 ± 0.071 <sup>ab</sup> |
| Σ (n-6)                            | 14.681 ± 2.032 <sup>a</sup> | 16.702 ± 0.501 <sup>a</sup> | 16.129 ± 0.669 <sup>a</sup> | 16.523 ± 0.717 <sup>a</sup> |
| Σ SFA                              | 47.528 ± 1.884 <sup>a</sup> | 41.346 ± 0.589 <sup>b</sup> | 42.096 ± 0.631 <sup>b</sup> | 41.485 ± 0.323 <sup>b</sup> |
| Σ MUFA                             | 36.633 ± 3.926 <sup>a</sup> | 40.670 ± 0.769 <sup>a</sup> | 40.377 ± 0.016 <sup>a</sup> | 40.704 ± 0.409 <sup>a</sup> |
| Σ PUFA                             | 15.839 ± 2.045 <sup>a</sup> | 17.983 ± 0.510 <sup>a</sup> | 17.528 ± 0.617 <sup>a</sup> | 17.811 ± 0.725 <sup>a</sup> |

Results expressed as mean ± standard deviation (SD) of triplicate. Values with different letters on the same line are significantly different ( $p < 0.05$ ) by Tukey's test. LAU: lauric acid; MYR: myristic acid; PA: palmitic acid; OA: oleic acid; LA: linoleic acid; CLA: conjugated linoleic acid; LNA: alpha-linolenic acid; GLA: gamma-linolenic acid; HEN: heneicosyl acid; DLA: di-homo- $\alpha$ -linolenic acid; ARA: arachidonic acid; EPA: eicosapentaenoic acid; LIG: lignoceric acid; DHA: docosahexaenoic acid; n-3: fatty acids from omega 3 family; n-6: fatty acids omega 6 family; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; RCHM: raw colostrum human milk; PastCHM: pasteurized and freeze-dried colostrum human milk; FdCHM: freeze dried colostrum human milk; PastFdCHM: pasteurized and freeze-dried colostrum human milk.

According to Visentainer et al.,<sup>31</sup> FA composition determines in the HM its nutritional and physical-chemical properties. Therefore, defining the FA composition based on diet and maternal age, as well as factors such as phase (colostrum, transition and mature) and feeding time (previous, intermediate, and posterior) is extremely important for the newborn's health.<sup>11,32</sup>

It can be considered that the 18:1n-9 is synthesized by infants mainly as an energy source, besides promoting fat absorption by the small intestine.<sup>8</sup> PA (16:0) is mostly in the central position (Sn-2) of the triacylglycerol molecule, presenting great importance for calcium absorption and intestinal composition.<sup>29,33</sup> It favors the action of pancreatic lipase, enabling the conversion of 16:0 into Sn-2 monoacylglycerol, directly related to hormonal levels, such as anandamide, a brain neurotransmitter with calming power for neonates, and also presenting potential improvement in intestinal discomfort.<sup>7,31</sup>

In addition to the above, among the prominent constituents of HM are the LA (18:2n-6) and  $\alpha$ -linoleic (LNA, 18:3n-3), which are precursors of ARA (20:4n-6) and DHA (22:6n-3), main sources in visual and cerebral development during perinatal progress and of great importance for neonates up to 7 days postpartum, or premature.<sup>34</sup> Although they can be synthesized from their respective precursors, conversion rates are insufficient. Thus, providing ARA and DHA at adequate concentrations in the diet is important for optimal development during pregnancy.<sup>35</sup>

It can be said that the structuring of physiological processes, as well as brain development and function, and immunological tissues required supply of certain rate of DHA per day, reaching a DHA content of at least ca. 0.3% of total FAs.<sup>36,37</sup> Among the findings in the present study regarding CHM even with applied treatments, the concentration is equal to 0.13% for DHA, indicating an important interaction of 18:3n-3 as its precursor, so that daily DHA levels are met and observing an adequate newborn development. While availability in HM is relatively low on EPA (0 to 0.12% by weight) and higher for ARA (0.08-1.1% by weight), similarly DHA (0.01-0.56% by weight).<sup>38</sup> In view of the results found, they presented within the standard, with significant differences ( $p > 0.05$ ) in EPA ( $0.067 \pm 0.007$  to  $0.225 \pm 0.070$ ), and similarly for ARA ranging from  $0.126 \pm 0.029$  to  $0.170 \pm 0.034$ , both cases of the FAs were negatively affected in

their concentrations.

Most official agencies around the world establish alternatives to maintain the biological safety of HM.<sup>9,15,39-41</sup> Consequently, studies evaluated Holder pasteurization with a temperature of 62.5 °C for 30 min, freeze drying, and/or pasteurization followed by freeze drying.<sup>42-46</sup> Changes in lipid content are predicted after application of treatments such as pasteurization and freeze-drying due to the temperature variations to which the samples are submitted.<sup>47</sup> Therefore, it is necessary the observation the occurrence of significant differences between the processing performed and the untreated sample, to verify the processes interference in the conservation of the CHM lipid profile.

The results expressed in Table 3 demonstrate that the application of the treatments decreased the medium chain fatty acids concentration, such as lauric acid (LAU 12:0), myristic acid (MYR 14:0) and 16:0, in relation to RCHM levels. Evaluating the numbers, the PastFdCHM sample in relation to RCHM had a decrease of 61% for 12:0, 38% for 14:0 and 12% for 16:0. For conjugated linoleic acid (CLA trans10, cis12), heneicosyl (HEN 21:0), di-homo- $\alpha$ -linolenic (DLA 20:3n-3) and lignoceric (LIG 24:0) there was a significant increase achieved for the treated samples in relation to RCHM.

Most of the MUFAs found (about 50%) and PUFAs (about 60%), among which are included some of the n-6, namely LA 18:2n-6 and GLA 18:3n-6, did not present significant differences ( $p < 0.05$ ) among the samples evaluated. Moltó-Puigmartí et al.<sup>48</sup> state that they did not find significant differences in the proportions of these FAs between pasteurized and untreated samples.

There were effects on the saturated fatty acids (SFA) sum, which presented total concentrations of  $47.528 \pm 1.884$ ,  $41.346 \pm 0.589$ ,  $42.096 \pm 0.631$  and  $41.485 \pm 0.323$  for the samples RCHM, PastCHM, FdCHM, and PastFdCHM, respectively, so that the RCHM sample differed significantly from the others. This fact demonstrates similarity to Neia et al.<sup>30</sup> results, which identified implications for SFA concentration when pasteurization and freeze-drying were applied in combination on CHM.

In general, 48% of the monounsaturated fatty acids found did not present significant difference between treatments, followed by 26% in which the RCHM differed from the others, 10% in which the PastCHM differed from the others and 16% which presented different behaviors. Thus, it was observed in the present study that the pasteurization and freeze drying partially influenced the concentration of FAs in the CHM. According to Meng et al.,<sup>4</sup> this may be related to the fact that temperature affects the stability of nutrients in HM, since the lipid structure can be modified. Another authors<sup>25</sup> points out that the pasteurization applied by human milk banks may imply the maintenance of lipid characteristics. A greater number of steps may also explain the possible differences obtained between the samples.<sup>47</sup>

Despite the observed changes, it is interesting to highlight that the sums related to the FA from the n-6 family, MUFA and PUFA showed no difference between the treatments, which points to an important result because these FA act in the synthesis of DHA, an essential component for brain development, constituting one of the reasons why breastfeeding premature babies with breast milk overlaps the use of commercial infant formulas.<sup>27</sup>

### **Lipid nutritional quality**

The importance performed by CHM lipid components on newborns is poorly documented, thus needing to be better investigated, since a lipid nutritional quality can promote health maintenance at different ages of life.<sup>6,49</sup> Six lipid nutritional quality indices were calculated according to the FA quantification obtained preliminary. Table 4 shows CHM lipid nutritional quality indices in different processes.

**Table 4:** Lipid nutritional quality indices of CHM for each treatment received

| Indice           | Sample                      |                             |                             |                             |
|------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                  | RCHM                        | PastCHM                     | FdCHM                       | PastFdCHM                   |
| AI               | 1.052 ± 0.085 <sup>a</sup>  | 0.713 ± 0.021 <sup>b</sup>  | 0.757 ± 0.019 <sup>b</sup>  | 0.727 ± 0.008 <sup>b</sup>  |
| TI               | 1.468 ± 0.100 <sup>a</sup>  | 1.162 ± 0.028 <sup>b</sup>  | 1.177 ± 0.023 <sup>b</sup>  | 1.159 ± 0.016 <sup>b</sup>  |
| H/H              | 1.305 ± 0.109 <sup>b</sup>  | 1.767 ± 0.053 <sup>a</sup>  | 1.700 ± 0.039 <sup>a</sup>  | 1.753 ± 0.012 <sup>a</sup>  |
| Σ (n-6)/ Σ (n-3) | 12.668 ± 1.623 <sup>a</sup> | 13.039 ± 0.307 <sup>a</sup> | 11.577 ± 1.094 <sup>a</sup> | 12.856 ± 0.892 <sup>a</sup> |
| (EPA) + (DHA)    | 0.202 ± 0.015 <sup>b</sup>  | 0.231 ± 0.025 <sup>b</sup>  | 0.354 ± 0.071 <sup>a</sup>  | 0.227 ± 0.019 <sup>b</sup>  |
| Σ PUFA/Σ SFA     | 0.332 ± 0.031 <sup>b</sup>  | 0.435 ± 0.014 <sup>a</sup>  | 0.417 ± 0.021 <sup>a</sup>  | 0.429 ± 0.021 <sup>a</sup>  |

Results expressed as mean ± standard deviation (SD) of triplicate. Values with different letters on the same line are significantly different ( $p < 0.05$ ) by Tukey's test. AI: atherogenicity index; TI: thrombogenicity index; H/H: ratio of hypocholesterolemic/hypercholesterolemic fatty acids, Σ (n-6)/ Σ (n-3): sum of the omega-6 family in ratio to the omega-3 family; Σ PUFA/Σ SFA: sum of polyunsaturated fatty acids in ratio of saturated fatty acids; (EPA) + (DHA) sum of eicosapentaenoic and docosahexaenoic fatty acids; SFA: saturated fatty acids; PUFA: polyunsaturated fatty acids; n-6: fatty acids from omega-6 family; n-3: fatty acids from omega-3 family; RCHM: raw colostrum human milk; PastCHM: pasteurized colostrum human milk; FdCHM: freeze dried colostrum human milk; PastFdCHM: pasteurized and freeze-dried colostrum human milk.

The atherogenicity index (AI) refers to the FA atherogenic potential. Among the samples analyzed, RCHM was the highest value found, and a significant difference was found between RCHM and samples that underwent a conservation treatment. Reference values for AI were not found in the literature, but it is known that the lower the AI value, the higher the lipid quality of food.<sup>50</sup> Thrombogenicity index (TI) presents the FA thrombogenic potential, the propensity to form clots in blood vessels. So, like AI, low values for TI are expected. For the analyzed samples, RCHM was the highest value found, and it presented a significant difference when compared to the treatments applied. Therefore, for both TI and AI, The RCHM presents lower lipid nutritional quality than samples submitted to some heat treatment.<sup>50</sup>

The H/H, according to Santos-Silva et al.,<sup>21</sup> indicates the specific effects of FAs on cholesterol metabolism in the human body, and higher values are desirable, as they generate greater health benefits. This is because hypocholesterolemic FAs reduce low density lipoprotein, preventing cardiovascular diseases, while hypercholesterolemic FAs increase blood cholesterol levels, consequently, increasing the coronary heart disease risk. The values found support the hypothesis that the samples of CHM that were submitted to some heat treatment present a higher nutritional quality lipidic than the RCHM, because the values for these samples were higher.

For the  $\Sigma$  (n-6)/  $\Sigma$  (n-3) ratio, high values indicate the pathogenesis of many diseases, while lower values exert a disease suppression effect. The ideal value of this ratio should be between 5 and 10. For the analyzed samples, no statistical difference was found, and all values are above 10<sup>51</sup>, which demonstrates that the treatments applied did not influence this aspect.

The Sum of EPA+DHA can simulate the dietary fat intake interaction, demonstrating the effects of these long-chain polyunsaturated fatty acids on human health, which perform functions to the pathophysiological mechanisms underlying immune function and neurodevelopment in newborns<sup>52</sup>. Among EPA+DHA, significant differences were found ( $p > 0.05$ ) between the FdCHM sample, being superior to the others, justified by the distinct EPA concentration.


The  $\Sigma$  PUFA/  $\Sigma$  SFA ratio allows point the generalized lipid nutritional quality, as it considers PUFA activity on SFA, and PUFAs can restrict low density lipoprotein (LDL) cholesterol and decrease plasma cholesterol levels<sup>50</sup>. However, the  $\Sigma$  PUFA/  $\Sigma$  SFA index may not be efficient to evaluate the fat nutritional value, since some SFA does not influence the increase in plasma cholesterol, besides ignoring the effects of MUFAs.<sup>53</sup> However, the data presented in Table 4 show that there was a significant difference ( $p > 0.05$ ) when comparing the pasteurization and lyophilization processes to untreated colostrum human milk (RCHM). Thus, it is suggested that the temperature applied in the samples, together with the melting point between the fatty acids saturation, influences the concentrations identified,<sup>49,54</sup> in addition to other factors such as handling and storage conditions.

### **Principal Component Analysis (PCA)**

A A multivariate exploratory technique to the PCA was performed to expand the visualization of data involving the CHM lipid quality. Figure 2 illustrates the plot graphs representing the loadings (variables, that are FA composition and lipid nutritional quality) and scores (namely as score 1 - RCHM, score 2 - PastCHM, score 3 - FdCHM and score 4 - PastFdCHM) from the similarity of the comparison between the samples, being possible to justify

the 88.81% total variance of the data by the analysis of PCA, where PC1 represents 71.90% and PC2 16.91%.

There was a cluster between the vast majority of FA data and lipid nutritional quality indices related to the negative quadrant of PC1 and PC2 (Figure 2a), thus indicating that the variables with significant differences are short chain fatty acids 4:0, 6:0, 8:0, 10:0, some monounsaturated like 14:1n-9 and 15:1n-9, in addition to 18:3n-3 and 22:6n-3. Thus, variations in lipid quality influenced by treatments such as pasteurization and freeze-dried are distinguished by PCA.



**Figure 2 .** Representation by graphs of lipid quality variables among treatments in human colostrum milk. (a) Graph of the similarity assessment between the variables (loadings). (b) Graph of the similarity assessment between the samples (scores).

It can also be observed from Figure 2b that the RCHM sample was distinct from among the others, positioned in the positive quadrant. It is possible to observe a predominant peculiarity referring to the SFA, 14:0, 15:0, and TI about the RCHM. It is justified that the degree of unsaturation of fatty acids in lipids influence fluidity, preventing fatty acids from grouping steadily, thus decreasing the melting temperature.<sup>57</sup> Temperature applications can degrade short-chain FAs, such as butyric (4:0), caproic (6:0), caprylic (8:0) and capric (10:0) acids present in the HM samples, which consequently will not be identified.<sup>8</sup>

In addition, the singularity to score 1 (RCHM) is restricted to the originality of the sample not treated by any treatment. On the other hand, the samples represented by scores 3

(FdCHM) and 4 (PastFdCHM) in Figure 2b show similarity with proximity to the positive PC2, which can be based on the effects of the application of freeze-drying, while score 2 (PastCHM) in negative PC2 particularizes the effects of pasteurization, with a proximity to score 4, a sample that was also applied pasteurization processing. Therefore, from the PCA it was possible to evaluate the similarity of lipid quality among the samples evaluated in this study.

## **Conclusions**

This study demonstrated that there are variations in the proximal composition, in the FAs composition and consequently in the lipid quality of human colostrum milk submitted to different conservation treatments (pasteurization, freeze-drying or pasteurization combined with freeze-drying) when compared to raw colostrum milk.

Regarding the proximal composition, no significant difference was observed between the pasteurized sample and the untreated sample. However, the sample in which there was a combination of pasteurization and freeze-drying differed from the sample only freeze-dried in relation to the contents of proteins, ash and, consequently, energy value. Moisture, carbohydrates and lipid content showed no significant difference.

Regarding the FA composition, of the 31 identified FAs, 14 did not present a significant difference between the different treatments, and the sum of FA of the n-6 family, MUFA and PUFA remained preserved. Among the FA influenced by the treatments, the medium chain (12:0, 14:0, 15:0, 16:0) stands out.

The results obtained for lipid nutritional quality are complementary for the evaluation of CHM, and the sum of the FA ratio of the n-6 and n-3 family did not show a difference for the different treatments. For the other aspects, there was difference, being interesting its evaluation in other studies.

When applying PCA on the lipid quality of the samples, different behaviors were observed for RCHM and PastCHM samples and similar behavior for FdCHM and PastFdCHM.

The results suggest that the application of pasteurization and freeze-drying processes are

adequate from the point of view of maintaining lipids in CHM, in addition to the prevalence of preserved FA compared to the total identified. However, new investigations must be conducted in view of the complexity of the HM matrix and the specificities of the processes employed, such as the evaluation of temperatures used in processes and storage.

### **Declaration of competing interest**

The authors declare no conflict of interest.

### **Acknowledgment**

The authors would like to thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação Araucaria, Fundação Cargill and Programa de Pesquisa para o SUS (PPSUS) for financial assistance; and to the research group APLE-A, and the Human Milk Bank of University Hospital of Maringá for its partnership and donation of human milk samples.

### **Author Contributions**

**Gislaine de Almeida Santana Ientz:** Investigation. Visualization. Formal analysis. Writing-original draft. Conceptualization.

**Eloize S. Alves:** Data curation. Writing- original draft. Writing – review & editing.

**Matheus C. Castro:** Writing- original draft.

**Giovana Frigo:** Writing – review & editing.

**Christyna Beatriz Genovez Tavares:** Visualization. Resources.

**Oscar O. Santos:** Investigation. Resources. Supervision.

**Jesui V. Visentainer:** Visualization. Resources. Conceptualization. Supervision. Funding acquisition.

### **References**

1. Léké, A.; Grognet, S.; Deforceville, M.; Gouldjil, S.; Chazal, C.; Kongolo, G.; Dzon, B. E.; Biendo, M.; *Clin. Nutri. Exp.* 2019, 26, 59. [Crossref]
2. Wesolowska, A.; Sinkiewicz-Darol, E.; Barbaska, O.; Bernatowicz-Lojko, U.; Borszewska-Kornacka, M. K.; van Goudoever, J. B.; *Nutrients* 2019, 11, 1169. [Crossref]
3. Manin, L. P.; Rydlewski, A. A.; Galuch, M. B.; Pizzo, J. S.; Zappiello, C. D.; Senes, C. E. R.; Santos, O. O.; *Visentainer, J. V.*; *J. Braz. Chem. Soc.* 2019, 30, 1579. [Crossref]
4. Meng, F.; Uniacke-Lowe, T.; Ryan, A. C.; Kelly, A. L.; *Trends Food Sci. Technol.* 2021, 112, 608. [Crossref]
5. Manin, L. P.; Rydlewski, A. A.; Alves, E. S.; Ponhozi, I. B.; Castro, M. C.; Saqueti, B. H. F.; Santos, O. O.; *Visentainer, J. V.*; *Res. Soc. Dev.* 2020, 9, e26891211136. [Crossref]
6. Akinbule, O. O.; Onabanjo, O. O.; Sanni, S. A.; Adegunwa, M. O.; Akinbule, A. S.; *Food Chem.* 2022, 391, 133227. [Crossref]
7. Demmelmair, H.; Koletzko, B.; *Best Pract. Res., Clin. Endocrinol. Metab.* 2018, 32, 57. [Crossref]
8. Rydlewski, A. A.; Pizzo, J. S.; Manin, L. P.; Zappiello, C. D.; Galuch, M. B.; Santos, O. O.; *Visentainer, J. V.*; *Rev. Virtual Quim.* 2020, 12, 155. [Crossref]
9. Martysiak-Żurowska, D.; Rożek, P.; Puta, M.; *Drying Technol.* 2022, 40, 615. [Crossref]
10. Mosca, F.; Gianni, M. L.; *Pediatr. Med. Chir.* 2017, 39, 155. [Crossref]
11. Castro, M. C.; Oliveira, F. S.; Alves, E. S.; Zacarias, J. M. V.; Alencar, J. B.; Silva, J. M.; *Visentainer, J. E. L.*; Santos, O. O.; *Visentainer, J. V.*; Ichisato, S. M.; *J. Braz. Chem. Soc.* 2023, 34, 201. [Crossref]
12. Halleux, V.; Pieltain, C.; Senterre, T.; Rigo, J.; *Semin. Fetal Neonatal Med.* 2017, 22, 23. [Crossref]
13. Agência Nacional de Vigilância Sanitária (ANVISA); Banco de Leite Humano: Funcionamento, Prevenção e Controle de Riscos; Diário Oficial da União: Brasília, Brazil, 2008. [Link] accessed in May 2023
14. dos Santos, V. J.; Baqueta, M. R.; Março, P. H.; Valderrama, P.; *Visentainer, J. V.*; *Food Anal. Methods* 2021, 14, 873. [Crossref]
15. Agência Nacional de Vigilância Sanitária (ANVISA); Resolução RDC No. 171, de 4 de setembro de 2006, Dispõe sobre o Regulamento Técnico para o Funcionamento de Bancos de Leite Humano; Diário Oficial da União: Brasília, Brazil, 2006. [Link] accessed in May 2023
16. Association of Official Analytical Chemists (AOAC); Official Methods of Analysis of the Association of Official Analytical Chemists; AOAC: Rockville, 2005. [Link] accessed in May 2023
17. Folch, J.; Lees, M.; Stanley, G. S.; *J. Biol. Chem.* 1957, 226, 497. [Crossref]
18. Food and Agriculture Organization (FAO); Food Energy - Methods of Analysis and Conversion Factors; FAO: Roma, 2003. [Link] accessed in May 2023
19. ISO 15885: Milk Fat - Determination of the Fatty Acid Composition by Gas-Liquid Chromatography, ISO: Geneva, 2002. [Link] accessed in May 2023
20. Ulbricht, T. L. V.; Southgate, D. A. T.; *Lancet* 1991, 338, 985. [Crossref]
21. Santos-Silva, J.; Bessa, R. J. B.; Santos-Silva, F. J. L. P. S.; *Livest. Prod. Sci.* 2002, 77, 187. [Crossref]
22. Food and Agriculture Organization (FAO); Nutritional Aspects of Cardiovascular Disease. In Report of the Cardiovascular Review Group-Committee on Medical Aspects of Food Policy. Department of Health: London, 1996. [Link] accessed in May 2023
23. Food and Agriculture Organization (FAO); Report of the Cardiovascular Review Group-Committee on Medical Aspects of Food Policy Nutritional Aspects of Cardiovascular Disease; Department of Health: London, 1996, p. 186. [Link] accessed in May 2023
24. Statistica, version 7.0 for Windows; Statsoft Inc., Statsorft, Tulsa, OK, USA, 2004.
25. dos Santos, V. J.; Baqueta, M. R.; Neia, V. J. C.; Souza, P. M.; Março, P. H.; Valderrama, P.; *Visentainer, J. V.*; *LWT* 2021, 147, 111645. [Crossref]
26. Blackshaw, K.; Wu, J.; Valtchev, P.; Lau, E.; Banati, R. B.; Dehghani, F.; Schindeler, A.; *Foods* 2021, 10, 2077. [Crossref]
27. Schipper, A. L. In Dietary Lipid Quality, Environment and the Developing Brain; Schipper, A. L., ed.; Rijksuniversiteit Groningen: Groningen, Netherlands, 2018, ch. 1. [Link] accessed in May 2023
28. Giuffrida, F.; Fleith, M.; Goyer, A.; Samuel, T. M.; Elmelegy- Masserey, I.; Fontannaz, P.; Cruz-Hernandez, C.; Thakkar, S. K.; Monnard, C.; de Castro, C. A.; Lavalle, L.; Rakza, T.; Agosti, M.; Al-Jashi, I.; Pereira, A. B.; Costeira, M.J.; Marchini, G.; Vanpee, M.; Stiris, T.; Stoiceau, S.; Silva, M. G.; Picaud, J. C.; Martinez- Costa, C.; Domellöf, M.; Billeaud, C.; *Eur. J.*

- Nutr. 2022, 61, 2167. [Crossref]
29. Rydlewski, A. A.; Manin, L. P.; Pizzo, J. S.; Silva, P. D.; da Silveira, R.; Tavares, C. B. G.; de Paula, M.; Pereira, O.; Santos, O. O.; Visentainer, J. V.; *J. Food Compos. Anal.* 2021, 100, 103797. [Crossref]
30. Neia, V. J. C.; Santos, P. D. S.; Tavares, C. B.; Paula, M. G.; Costa, S. C.; Zacarias, J. M.; Alencar, J. B.; Silveira, R.; Santos, O. O.; Visentainer, J. E.; Visentainer, J. V.; *J. Braz. Chem. Soc.* 2023, 34, 54. [Crossref]
31. Visentainer, J. V.; Santos, O. O.; Maldaner, L.; Zappiello, C.; Neia, V.; Visentainer, L.; Pelissari, L.; Pizzo, J.; Rydlewski, A.; Silveira, R.; Galuch, M.; Visentainer, J. L. In *Biochemistry and Health Benefits of Fatty Acids*; Waisundara, V. Y.; Blumenberg, M., eds.; IntechOpen: London, UK, 2018. [Crossref]
32. Alves, E. S.; Castro, M. C.; Saqueti, B. H.; Manin, L. P.; Silveira, R. D.; Souza, P. M.; Santos, O. O.; Visentainer, J. V.; *J. Braz. Chem. Soc.* 2021, 32, 1884. [Crossref]
33. Bar-Yoseph, F.; Lifshitz, Y.; Cohen, T.; *Prostaglandins, Leukotrienes Essent. Fatty Acids* 2013, 89, 139. [Crossref]
34. Kelishadi, R.; Hadi, B.; Iranpour, R.; Khosravi-Darani, K.; Mirmoghtadaee, P.; Farajian, S.; Poursafa, P.; *J. Res. Med. Sci.* 2012, 17, 824. [Link] accessed in May 2023
35. Bahreynian, M.; Feizi, A.; Daniali, S. S.; Kelishadi, R.; *Child: Care, Health Dev.* 2023, 49, 137. [Crossref]
36. Koletzko, B.; *Ann. Nutr. Metab.* 2016, 69, 27. [Crossref]
37. Hopperton, K. E.; Pitino, M. A.; Walton, K.; Kiss, A.; Unger, S. L.; O'Connor, D. L.; Bazinet, R. P.; *Lipids* 2022, 57, 197. [Crossref]
38. Kris-Etherton, P. M.; Grieger, J. A.; Etherton, T. D.; *Prostaglandins, Leukotrienes Essent. Fatty Acids* 2009, 81, 99. [Crossref]
39. Davis International Milk Genomics Consortium, Milk Banks Around the World, <https://www.milkgenomics.org/?splash=milk-banks-around-the-world>, accessed in May 2023.
40. European Milk Bank Association (EMBA); *Is Donor Milk Always Pasteurised or Heat-Treated?* European Milk Bank Association: Milan, 2023. [Link] accessed in May 2023
41. U.S. Breastfeeding Committee (USBC); *Active Legislation*; U.S. Breastfeeding Committee: Washington, 2023. [Link] accessed in May 2023
42. Human Milk Banking Association of North America (HMBANA); *How to Help: Donate Milk*; Human Milk Banking Association of North America, Fort Worth, 2023. [Link] accessed in May 2023
43. Souza, P. M.; Ponhozi, I. B.; Manin, L. P.; Rydlewski, A. A.; Alves, E. S.; Cruz, V. H. M.; Santos, O. O.; Visentainer, J. V.; *Research, Soc. Dev.* 2022, 11, e554111335770. [Crossref]
44. Giribaldi, M.; Nebbia, S.; Briard-Bion, V.; Jardin, J.; Peila, C.; Coscia, A.; Dupont, D.; Cavallarín, L.; Deglaire, A.; *Food Chem.* 2022, 369, 130998. [Crossref]
45. Wesolowska, A.; Dobrowolska, I.; Sinkiewicz-Darol, E.; Barbarska, O.; Niewada, M.; Golicki, D.; *Value Health Reg.* 2020, 22, 54. [Crossref]
46. Blackshaw, K.; Wu, J.; Proschogo, N.; Davies, J.; Oldfield, D.; Schindeler, A.; Banati, R. B.; Dehghani, F.; Valtchev, P.; *Food Chem.* 2021, 373, 131402. [Crossref]
47. Nessel, I.; Khashu, M.; Dyal, S. C.; *Prostaglandins, Leukotrienes Essent. Fatty Acids* 2019, 149, 8. [Crossref]
48. Moltó-Puigmartí, C.; Castellote, A. I.; Carbonell-Estrany, X.; López-Sabater, M. C.; *Clin. Nutr.* 2011, 30, 116. [Crossref]
49. Lopez, C.; Briard-Bion, V.; Bourgaux, C.; Pérez, J.; *Food Res. Int.* 2013, 54, 1541. [Crossref]
50. Chen, J.; Liu, H.; *Int. J. Mol. Sci.* 2020, 21, 5695. [Crossref]
51. Simopoulos, A. P.; *Food Rev. Int.* 2008, 20, 77. [Crossref]
52. Salinas, F. C.; Ramón, A. M.; Ferrer, F. J. C.; Domingo-Carnice, A.; Cordobilla, B.; Domingo, J. C.; *Nutrients* 2022, 14, 4956. [Crossref]
53. Tiencheu, B.; Claudia, A. C.; Achidi, A. U.; Ngongang, E. F. T.; Tenyang, N.; Djikeng, F. T.; Fossi, B. T.; *Food Sci. Nutr.* 2021, 9, 4156. [Crossref]
54. Folleyan, A. J.; Anawe, P. A. L.; Aladejare, A. E.; Ayeni, A. O.; *Energy Rep.* 2019, 5, 793. [Crossref]
55. Zou, X. Q.; Guo, Z.; Huang, J. H.; Jin, Q. Z.; Cheong, L. Z.; Wang, X. G.; Xu, X. B.; *J. Agric. Food Chem.* 2012, 60, 7158. [Crossref]